Experience

• Capital Markets

  • Schrödinger in its initial public offering and subsequent follow-on public offering of approximately $579 million
  • Inozyme Pharma in its $128.8 million initial public offering, $73.1 million follow-on offering and $69 million follow-on offering
  • Fulcrum Therapeutics in its $72 million initial public offering, $68.5 million private placement, $50.6 million follow-on offering and $144.2 million follow-on offering
  • Cue Health in its $200 million initial public offering
  • Nuvalent in its $281.6 million follow-on public offering 
  • Solid Biosciences in its $200 million follow-on public offering
  • Verve Therapeutics in its $225 million follow-on public offering and in its $125 million follow-on public offering
  • Ocular Therapeutix, Inc. in its $115 million follow-on public offering and its $325 million private placement
  • Curis in its $15.1 million registered direct offering
  • Astria Therapeutics in its $125 million underwritten registered direct offering
  • Xilio Therapeutics in its $50 million offering
  • Underwriters in Viridian’s $254 million follow-on public offering
  • Casella Waste Systems in its $517.5 million follow-on public offering 
  • KALA BIO in its $134 million public offering and $10.75 million private placement
  • Numerous ATM offerings for clients